ScripMerck & Co. is awaiting regulatory approvals for its subcutaneous version of PD-1 inhibitor pembrolizumab, and its successful head-to-head trial against the original intravenous Keytruda (pembroli
ScripJohnson & Johnson’s combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) in certain patients with non-small cell lung cancer (NSCLC) stands to expand its use as a first-line treat
Pink SheetEarly evidence suggests US Food and Drug Administration Commissioner nominee Martin Makary could be a more “conventional” agency leader than others in President Trump’s second administration. Makary i
HBW InsightEarly evidence suggests US Food and Drug Administration Commissioner nominee Martin Makary could be a more “conventional” agency leader than others in President Trump’s second administration. Makary i